title: Treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis with high or conventional doses of ceftazidime.
abstract: In cystic fibrosis patients with Pseudomonas aeruginosa colonization and increasing pulmonary infection, ceftazidime 150 mg/kg/day was compared with 320 mg/kg/day. Changes in clinical findings, laboratory tests, pulmonary function and chest radiographs were evaluated after 14 days of treatment in hospital. Both treatments were associated with a significant improvement, but the higher dose did not offer an additional benefit. An increase in alanine aminotransferase (ALT) occurred after both treatments; with a significantly greater increase after the high-dose therapy (mean increase +/- S.E.M. 8% +/- 2% vs 2% +/- 1 %; P < 0.01). All but one of the ALT values after treatment were within normal limits.
authors.affiliation: Department of Pediatrics, University Hospital of Leuven, Belgium. christiane.deboeck@uz.kuleuven.ac.be
authors.forename: K
authors.initials: K
authors.lastname: De Boeck
authors.forename: L
authors.initials: L
authors.lastname: Breysem
mesh_terms: D000293:Adolescent; D000410:Alanine Transaminase / Q000097:blood / Q000187:drug effects; D001799:Blood Sedimentation / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002442:Ceftazidime / Q000008:administration & dosage / Q000627:therapeutic use*; D002511:Cephalosporins / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D003404:Creatinine / Q000097:blood; D003550:Cystic Fibrosis / Q000150:complications* / Q000382:microbiology; D003627:Data Interpretation, Statistical; D004305:Dose-Response Relationship, Drug; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects / Q000502:physiology; D006454:Hemoglobins / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D007958:Leukocyte Count / Q000187:drug effects; D008168:Lung / Q000187:drug effects / Q000382:microbiology; D008171:Lung Diseases / Q000188:drug therapy* / Q000382:microbiology / Q000503:physiopathology; D008176:Lung Volume Measurements; D008297:Male; D009504:Neutrophils / Q000166:cytology / Q000187:drug effects; D010359:Patient Readmission; D010976:Platelet Count / Q000187:drug effects; D011552:Pseudomonas Infections / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000302:isolation & purification; D012123:Pulmonary Ventilation / Q000187:drug effects / Q000502:physiology; D012008:Recurrence; D012129:Respiratory Function Tests; D013997:Time Factors; D016896:Treatment Outcome; D014680:Veins; D014797:Vital Capacity / Q000187:drug effects / Q000502:physiology
chemical_list: D002511:Cephalosporins; D006454:Hemoglobins; D002442:Ceftazidime; D003404:Creatinine; D000410:Alanine Transaminase